Screener
Discontinued — last reported Q4 '25
CapEx at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Syndax Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:04 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-076536
| Line item | Years Ended December 31, 2025 | Years Ended December 31, 2024 | Years Ended December 31, 2023 |
|---|---|---|---|
| Accrued expenses and other current liabilities | 42,167 | 19,139 | 14,867 |
| Net cash used in operating activities | (322,980) | (274,903) | (160,601) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||
| Purchases of property and equipment | (187) | — | — |
| Purchases of short and long-term investments | (195,807) | (557,052) | (354,606) |
| Proceeds from maturities of short-term investments | 486,030 | 337,277 | 472,215 |
| Net cash provided by (used in) investing activities | 290,036 | (219,775) | 117,609 |
| CASH FLOWS FROM FINANCING ACTIVITIES: |
Item 16. Form 10-K Summary
FAQ
- What is Syndax Pharmaceuticals's capex?
- Syndax Pharmaceuticals (SNDX) reported capex of $46.75K in Q4 2025.
- What is the long-term trend for Syndax Pharmaceuticals's capex?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's capex has grown at a 9.7% compound annual growth rate (CAGR), from $129K to $187K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Syndax Pharmaceuticals's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude